India  

Drugs Controller General of India

Drugs Controller General of India    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Drugs Controller General of India:

Drugs Controller General of India (DCGI) is the head of department of the Central Drugs Standard Control Organization of the Government of India responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids, vaccines, and sera in India. Drugs Controller General of India, comes under the Ministry of Health & Family Welfare. DCGI also sets standards for manufacturing, sales, import, and distribution of drugs in India.

0
shares
ShareTweetSavePostSend
 

Covid update: Decongesting jails; DRDO's new oral drug; task force for oxygen [Video]

Covid update: Decongesting jails; DRDO's new oral drug; task force for oxygen

From DCGI approving new anti-Covid drug, to health ministry issues new rules for hospital admissions, here are the top updates on the coronavirus. DCGI approved a new anti-Covid oral drug, which has..

Credit: HT Digital Content     Duration: 03:24Published
DCGI approves DRDO's anti-COVID drug helpful in faster recovery [Video]

DCGI approves DRDO's anti-COVID drug helpful in faster recovery

Drugs Controller General of India (DCGI) on May 08 approved emergency use DRDO's anti-COVID drug which the agency said will be helpful in faster recovery of hospitalised patients. While speaking to..

Credit: ANI     Duration: 02:44Published
What is 2-DG: New drug approved for Covid emergency use | Oneindia News [Video]

What is 2-DG: New drug approved for Covid emergency use | Oneindia News

The Drugs Controller General of India has granted permission for emergency use of therapeutic application of drug 2-deoxy-D-glucose or 2-DG as adjunct therapy. This was used to treat cancer and showed..

Credit: Oneindia     Duration: 01:24Published
Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases [Video]

Zydus' Virafin gets emergency use approval for treating moderate COVID-19 cases

The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults. A release by..

Credit: ANI     Duration: 02:01Published

You Might Like


Potential cancer drug repurposed for Covid-19 by DRDO, Dr Reddy's gets DCGI nod for emergency use

A potential cancer drug repurposed for Covid-19 treatment -- 2-deoxy-D-glucose (2-DG) – has received the Drugs Controller General of India (DCGI) nod for emergency use as adjunct therapy for..
IndiaTimes - Published

DCGI approves anti-Covid drug developed by DRDO for emergency use

The Drugs Controller General of India’s (DCGI) has approved an anti-Coviddrug - 2-deoxy-D-glucose (2-DG) for emergency use. This has been developed by the Institute of Nuclear Medicine and Allied..
IndiaTimes - Published Also reported by •DNA

Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin


IndiaTimes - Published

Zydus Cadila gets DCGI nod for hepatitis drug for Covid-19 treatment

Drug firm Zydus Cadila on Friday said it has received restricted emergency use approval from the Indian drug regulator for the use of Pegylated Interferon alpha-2b (PegIFN) in treating moderate..
IndiaTimes - Published

Zydus Cadila's 'Virafin' gets DCGI nod for emergency use to treat COVID-19 patients

The company has said that 91.15 per cent of patients treated with the drug were RT-PCR negative by day seven.
DNA - Published

Health ministry issues regulatory pathways for foreign-produced Covid-19 vaccines

The Central Drugs Standards Control Organisation (CDSCO) headed by Drugs Controller General of India (DCGI) has explained that it prepare detailed guidelines specifying regulatory pathway for approval..
IndiaTimes - Published

Sputnik V cleared for launch in India: Five things you need to know about Russian Covid-19 vaccine

Dr Reddy's Laboratories said on Tuesday it has received permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations...
IndiaTimes - Published

Expert panel clears Sputnik V for ‘emergency use’, drug regulator’s nod expected soon

Amid concerns about the need to step up Covid-19 vaccination, India is soon expected to get its third shot against the infection with the drug regulator’s subject expert committee on Monday..
IndiaTimes - Published

Russia hopes approval to Sputnik-V vaccine by DCGI will be completed soon

Russia on Monday hoped that the Drug Controller General of India (DCGI) will soon complete the approval process for the Sputnik-V coronavirus vaccine after it was recommended for use in India by a..
IndiaTimes - Published

Covid-19: Government's expert panel allows clinical trials for third dose of Covaxin

Bharat Biotech presented amendments to the subject expert committee of the Drugs Controller General of India (DCGI) in the approved Phase 2 clinical trial protocol for administration of booster dose..
IndiaTimes - Published

Dr Reddy's initiates process for emergency use authorisation of Sputnik V

Dr Reddy's Laboratories said on Friday it has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorisation of human adenoviral vector-based platform vaccine..
IndiaTimes - Published

Serum Institute seeks DCGI nod for clinical trials of Covid-19 vaccine Covavax


IndiaTimes - Published

Bharat Biotech to begin Phase-1 trials of its intranasal vaccine for Covid-19 in Feb-March

Buoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI)for its Covid-19 vaccine Covaxin, Bharat Biotech has said Phase-1 clinical trials of its new..
IndiaTimes - Published

From abroad, Rahul directing Cong rumour-mongering: BJP

I​ntensifying attack on Congress for questioning the DCGI’s approval to Covid vaccines, BJP on Monday said Rahul Gandhi, while on a vacation abroad, choreographed rumour-mongering by enlisting his..
IndiaTimes - Published

DCGI allows Bharat Biotech to conduct vaccine trials on children above 12

Covaxin has already been used on children above 12 in phase I and II trials and has been found safe.
DNA - Published

Like Putin and Joe Biden, PM Modi should also get the first vaccine shot, says Cong leader

The DCGI on Sunday approved Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use.
DNA - Published

Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for Covid-19 vaccine


IndiaTimes - Published

Great milestone in India's scientific capability: Bharat Biotech after DCGI approval to Covaxin

The Hyderabad-based vaccine maker expressed its delight after DCGI granted permission for emergency use of its Covid-19 vaccine.
DNA - Published

Covid-19 vaccines 110% safe, impotency rumours complete nonsense: DCGI

As India gears up for the world's largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the Covid-19 vaccines regarding impotency, rubbishing..
IndiaTimes - Published

'Watershed moment in India's battle against COVID': Politicos react over emergency use approval

DCGI approved Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use.
DNA - Published

'Proud that two made in India vaccines given emergency use approval': PM Modi after DCGI nod

PM Modi also extended his gratitude to doctors, medical staff, scientists, sanitation workers and all 'Corona warriors' for the outstanding work.
DNA - Published

Covishield COVID-19 vaccine ready to roll out in coming weeks: SII's Adar Poonawalla

Poonawalla's remarks came soon after DCGI approved Serum Institute's 'Covishield' vaccine for restricted emergency use in India.
DNA - Published

DCGI approves Oxford's Covishield and Bharat Biotech's Covaxin vaccines for restricted emergency use


IndiaTimes - Published

BREAKING: DCGI grants approval to Serum Institute, Bharat Biotech's COVID-19 vaccines

The approval comes after the clearances from the Subject Expert Committee (SEC).
DNA - Published

Bharat Biotech’s Covaxin too gets nod for emergency use

India's vaccine rollout will begin with the availability of two jabs- Oxford-Astra Zeneca's Covishield and Bharat Biotech's homegrown Covaxin- with the Drugs Controller General of India expected to..
IndiaTimes - Published

Covaxin vaccine: DCGI panel to meet Bharat Biotech officials shortly


IndiaTimes - Published

Happy New Year: Expert panel clears Oxford vaccine for India

India moved closer to the rollout of its vaccination plan against Covid-19 with the subject expert committee of the drug regulator on Friday recommending emergency-use authorisation (EUA) for Serum..
IndiaTimes - Published

Probably we will have a very happy New Year: DCGI on Covid-19 vaccine

India is likely to have a Covid-19 vaccine in the New Year, Drug Controller General of India V G Somani hinted on Thursday. Speaking at a webinar, Somani said the most important thing is that the..
IndiaTimes - Published

Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1

Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an..
IndiaTimes - Published

COVID-19 vaccine: Serum Institute seeks emergency use authorisation for Covishield in India

The Serum Institute of India is the second company with a COVID-19 vaccine candidate to seek emergency use authorisation from the DCGI in India.
DNA - Published Also reported by •IndiaTimes

Pfizer becomes first pharma company in India to seek emergency use nod for its Covid-19 vaccine

Pfizer India has become the first pharmaceutical firm to approach the Drugs Controller General of India (DCGI) seeking an emergency use authorisation for its Covid-19 vaccine in the country. It is to..
IndiaTimes - Published

DCGI finds no link between Covid vaccine shot and 'adverse' reaction in Chennai volunteer during trial: Sources


IndiaTimes - Published

COVID-19 vaccine: Covidshield may be ready for rollout by Dec, says Serum Institute CEO

Covidshield has shown promising results during trials, but a lot depends on the approvals coming through from the Drugs Controller General Of India.
DNA - Published

ICMR issues advisory on CRISPR technology-based SARS CoV-2 test

The Indian Council of Medical Research (ICMR) on Thursday issued an advisory on the CRISPR SARS CoV-2 test that has been approved by the Drugs Controller General of India for Covid-19 detection. As..
IndiaTimes - Published

Russian Sputnik V Covid-19 vaccine to be tested on 100 Indian volunteers

The Russian Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General (DCGI) told Sputnik on..
IndiaTimes - Published

Dr Reddy's gets DCGI go-ahead to conduct Phase 2/3 human trials of Sputnik V in India

After the Indian drug regulator turned down Dr. Reddy’s Laboratories Ltd’s proposal earlier this month to conduct direct Phase-3 human trials for the Russian Covid-19 vaccine Sputnik V, the company..
IndiaTimes - Published

Bharat Biotech asked to submit complete phase 2 data of its Covid-19 vaccine before phase 3 trial

Bharat Biotech, which had sought DCGI's nod for conducting phase-3 clinical trials of its Covid-19 vaccine candidate, has been asked to submit complete safety and immunogenicity data of the ongoing..
IndiaTimes - Published

DCGI nod to Phase-1 human trials of 'antisera' with potential to treat Covid-19

The Drugs Controller General of India has given permission for conducting Phase-1 human clinical trial for an "antisera" that was developed by injecting inactivated SARS-CoV-2 in horses and can be a..
IndiaTimes - Published

Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asks

On September 16, the Drugs Controller General of India (DCGI) allowed the Serum Institute of India (SII) to restart its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
DNA - Published

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
DNA - Published

Serum Institute to resume vaccine trials after DCGI nod


IndiaTimes - Published

Will resume Covid-19 vaccine trials after DCGI nod: Serum Institute


IndiaTimes - Published

DCGI orders Serum Institute of India to suspend recruitment for Oxford Covid-19 vaccine trials


IndiaTimes - Published

Serum pauses trials of Oxford vaccine after DCGI’s notice


IndiaTimes - Published

Serum Institute gets DCGI notice over Oxford Covid-19 vaccine trial suspension by AstraZeneca abroad

The central drug regulator has issued a show-cause notice to Serum Institute of India (SII) for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine..
IndiaTimes - Published

Covid-19: Subject Expert Committee seeks DCGI's nod to use hepatitis injection for phase III clinical trial


IndiaTimes - Published


 Page 1  〉